Fentanyl B. Braun

What Is Fentanyl B. Braun and What Is It Used For?

Fentanyl B. Braun contains the active substance fentanyl (as fentanyl citrate), a synthetic opioid that acts primarily on mu-opioid receptors in the central nervous system. It belongs to the pharmacological group of opioid analgesics and is classified under ATC code N01AH01 (fentanyl, anaesthetic adjuvants). Fentanyl is one of the most widely used opioids in modern anaesthetic practice worldwide, featured on the WHO Model List of Essential Medicines as an indispensable medication for surgical care.

The drug is supplied as a clear, colourless aqueous solution for injection at a concentration of 50 micrograms per millilitre. It is available in glass ampoules of 2 ml (containing 100 micrograms fentanyl) and 10 ml (containing 500 micrograms fentanyl). Each ampoule is intended for single use only, and any unused solution must be discarded after opening.

Approved Clinical Indications

Fentanyl B. Braun is authorised for the following clinical uses, all of which require a hospital setting with appropriate monitoring and resuscitation equipment:

• Analgesic supplement to general anaesthesia: Fentanyl is administered intravenously during surgery to provide intense pain relief as part of balanced anaesthesia alongside inhaled anaesthetics and neuromuscular blocking agents. Its rapid onset (within 1–2 minutes of intravenous injection) and short duration of action (30–60 minutes) make it ideal for intraoperative pain management.
• Sole anaesthetic agent (high-dose technique): In cardiac surgery and other major procedures, fentanyl may be used at higher doses as the primary anaesthetic, providing cardiovascular stability that is particularly valuable in patients with compromised cardiac function.
• Supplement to regional anaesthesia: Fentanyl can be added to local anaesthetic techniques such as epidural or spinal anaesthesia to enhance pain relief during and after surgical procedures.
• Intensive care sedation and analgesia: In critically ill patients requiring mechanical ventilation, fentanyl provides effective sedation and pain relief. Its predictable pharmacokinetics allow for precise titration via continuous intravenous infusion.

Fentanyl's pharmacological profile is characterised by its high lipophilicity, which allows rapid penetration of the blood-brain barrier, contributing to its fast onset of action. The drug is approximately 50 to 100 times more potent than morphine on a weight-for-weight basis, meaning that very small doses produce significant analgesic effects. According to guidelines published by the European Society of Anaesthesiology and Intensive Care (ESAIC) and the American Society of Anesthesiologists (ASA), fentanyl remains a cornerstone of modern anaesthetic practice due to its predictable pharmacology and wide therapeutic index when used by trained professionals.

What Should You Know Before Taking Fentanyl B. Braun?

Before Fentanyl B. Braun is administered, a thorough pre-anaesthetic assessment is conducted by the treating physician. This assessment evaluates your overall health status, identifies potential risk factors, and ensures that appropriate precautions are in place. The following information is essential for the safe use of this medication.

Contraindications

Fentanyl B. Braun must not be administered if you have a known allergy (hypersensitivity) to fentanyl, other opioid analgesics (such as morphine, sufentanil, or remifentanil), or any of the other ingredients in this medicine (sodium chloride, water for injections). Allergic reactions to opioids can range from skin rashes to severe anaphylaxis, a life-threatening emergency requiring immediate treatment.

Warnings and Precautions

Your doctor will exercise particular caution and may adjust the dose or monitoring intensity if you have any of the following conditions:

• Respiratory compromise: Any impairment of lung function, severe asthma, chronic obstructive pulmonary disease (COPD), or conditions affecting the respiratory centre in the brain. Fentanyl depresses breathing and can worsen these conditions.
• Raised intracranial pressure: Head injuries, brain tumours, or conditions causing cerebral oedema. Fentanyl can increase intracranial pressure and may mask neurological signs.
• Cardiovascular instability: Low blood pressure (hypotension) or reduced blood volume (hypovolaemia). Fentanyl can cause further drops in blood pressure and heart rate, including bradycardia and, in rare cases, cardiac arrest.
• Phaeochromocytoma: A tumour of the adrenal glands that produces excess catecholamines. Fentanyl may trigger dangerous hypertensive crises in these patients.
• Biliary tract disease: Fentanyl can cause spasm of the sphincter of Oddi, increasing pressure in the bile ducts and potentially worsening symptoms of gallstone disease or cholangitis.
• Bowel obstruction or inflammatory bowel disease: Opioids reduce gut motility and can worsen obstructive conditions.
• Myasthenia gravis: A neuromuscular disorder that may be exacerbated by opioid-induced muscle rigidity and respiratory depression.
• Hepatic or renal impairment: Fentanyl is metabolised in the liver (primarily by CYP3A4) and its metabolites are excreted by the kidneys. Impaired organ function can lead to drug accumulation and prolonged effects.
• Hypothyroidism: Reduced thyroid function can enhance sensitivity to opioid effects, particularly respiratory depression.
• Prostatic hypertrophy: Opioids can cause urinary retention, which may be exacerbated in patients with enlarged prostate glands.
• Obesity: Dosing in obese patients requires careful calculation, often based on ideal or lean body weight rather than total body weight, to avoid excessive dosing.

Muscle Rigidity

Fentanyl can cause skeletal muscle rigidity, including rigidity of the chest wall muscles (sometimes called “wooden chest syndrome”). This is a well-documented opioid effect that can severely impair ventilation and make bag-mask ventilation difficult or impossible. The risk is increased with rapid intravenous injection and higher doses. Chest wall rigidity can be prevented or treated by slow intravenous injection, pre-medication with benzodiazepines, or administration of neuromuscular blocking agents. Non-epileptic myoclonic movements may also occur during treatment.

Dependence and Tolerance

Prolonged or repeated use of fentanyl can lead to tolerance (diminished effect at the same dose), physical dependence (withdrawal symptoms upon discontinuation), and psychological addiction. These risks are particularly relevant in intensive care settings where patients may receive fentanyl infusions for extended periods. Patients with a personal or family history of substance misuse, smoking, or psychiatric conditions (depression, anxiety, personality disorders) are at increased risk. Your doctor will carefully weigh the benefits against risks and monitor for signs of dependence throughout treatment.

If treatment with fentanyl is discontinued after prolonged use, the dose should be reduced gradually to prevent withdrawal symptoms, which may include nausea, vomiting, diarrhoea, anxiety, chills, tremors, and sweating. Additionally, some patients may develop opioid-induced hyperalgesia – a paradoxical increase in pain sensitivity despite increasing opioid doses. If this occurs, the physician may need to reduce the dose or switch to an alternative analgesic approach.

Pregnancy and Breastfeeding

Fentanyl B. Braun is generally not recommended during pregnancy or labour (including caesarean section). The drug crosses the placental barrier and can suppress spontaneous breathing in the newborn, potentially requiring immediate neonatal resuscitation with an opioid antagonist. If a mother receives fentanyl during pregnancy, there is also a risk of neonatal opioid withdrawal syndrome in the infant after birth.

During caesarean section, fentanyl may only be administered after the baby has been delivered and the umbilical cord has been clamped. An opioid antagonist must always be readily available for the newborn. Fentanyl is excreted in breast milk, and breastfeeding should be avoided for at least 24 hours after receiving the medication to prevent opioid exposure in the nursing infant.

Children

The safety and efficacy of fentanyl in children under 2 years of age have not been established. In children who breathe spontaneously (i.e., not on mechanical ventilation), fentanyl for analgesic procedures should only be used as part of a structured anaesthesia or sedation protocol, with experienced personnel and immediate access to intubation equipment in case of chest wall rigidity or respiratory arrest.

Driving and Operating Machinery

After receiving Fentanyl B. Braun, patients must not drive or operate machinery for at least 24 hours. The drug impairs alertness, coordination, and reaction time. Patients should arrange for someone to accompany them home after hospital discharge and must avoid alcohol during the recovery period. The treating physician will advise when it is safe to resume these activities.

Sodium Content

This medicine contains 3.54 mg sodium (the main component of table salt) per millilitre, equivalent to approximately 0.2% of the WHO-recommended maximum daily sodium intake for adults. This should be considered for patients on a sodium-restricted diet.

How Does Fentanyl B. Braun Interact with Other Drugs?

Drug interactions with fentanyl can be life-threatening. Before administration, the anaesthetist must have a complete list of all medications the patient is taking, including prescription drugs, over-the-counter medicines, and herbal supplements. The following interactions are of particular clinical importance.

Major Interactions

Other Significant Interactions

Several additional drug classes interact with fentanyl and require careful clinical consideration:

• Clonidine (antihypertensive): May potentiate the hypotensive effects of fentanyl and enhance sedation. Blood pressure monitoring is essential.
• Cimetidine (H2-receptor antagonist): Inhibits hepatic metabolism of fentanyl, potentially leading to increased plasma concentrations and prolonged effects.
• Antiretroviral agents (e.g., ritonavir for HIV): Potent CYP3A4 inhibitors that can dramatically increase fentanyl levels, requiring significant dose reductions.
• Antiepileptic drugs (phenytoin, carbamazepine, valproate): CYP3A4 inducers like phenytoin and carbamazepine may reduce fentanyl efficacy by accelerating its metabolism.
• Gabapentin and pregabalin: May enhance CNS depression when used concurrently with fentanyl, increasing the risk of excessive sedation and respiratory depression.
• Neuromuscular blocking agents: The doses of anaesthetic induction agents (e.g., etomidate, propofol) and muscle relaxants (e.g., midazolam) may need to be reduced when co-administered with fentanyl.
• Alcohol: If fentanyl is administered to a patient who has consumed alcohol, the effects of both substances are significantly potentiated, increasing the risk of severe respiratory depression and cardiovascular collapse.

What Is the Correct Dosage of Fentanyl B. Braun?

Fentanyl B. Braun is exclusively administered by physicians experienced in anaesthesiology and intensive care medicine. Dosing is highly individualised and depends on the clinical indication, patient characteristics, type and duration of surgery, concurrent medications, and the patient's response. The following dosing information reflects general guidelines based on international anaesthetic practice.

Adults

The dose of fentanyl is calculated based on body weight, the nature and expected duration of the surgical procedure, and whether it is used as a supplement to other anaesthetics or as the primary analgesic. In obese patients, dosing should be based on ideal body weight rather than actual weight to prevent overdosing.

Children (Over 2 Years)

In paediatric patients over 2 years of age, fentanyl dosing is based on body weight. Children typically receive 1–3 mcg/kg for minor procedures and up to 5 mcg/kg for major procedures, administered intravenously. Continuous infusion rates in paediatric ICU patients are typically 0.5–2 mcg/kg/hour. As with adults, the dose is carefully titrated to the individual response, and continuous cardiorespiratory monitoring is mandatory. The safety and efficacy of fentanyl in children under 2 years have not been established.

Elderly Patients

Elderly patients (over 65 years) generally require reduced doses of fentanyl. Ageing is associated with decreased hepatic blood flow, reduced hepatic enzyme activity, and increased sensitivity to opioid effects. Initial doses should typically be 50–75% of the standard adult dose, with careful titration based on clinical response. Extended monitoring is recommended due to the potential for prolonged drug effect in this population.

Patients with Hepatic or Renal Impairment

Fentanyl is primarily metabolised in the liver by the cytochrome P450 enzyme CYP3A4. Patients with significant liver disease may have impaired clearance, leading to drug accumulation and prolonged effects. Similarly, although fentanyl metabolites (primarily norfentanyl, which is inactive) are excreted renally, severe kidney impairment can affect overall drug handling. Dose reductions and extended monitoring intervals are advised in both situations.

Overdose

Fentanyl overdose is extremely unlikely in the hospital setting, as the drug is administered by trained specialists with continuous monitoring. However, if an overdose occurs, symptoms may include:

• Severe respiratory depression or respiratory arrest
• Loss of consciousness progressing to coma
• Cardiovascular collapse (hypotension, circulatory failure)
• Muscle rigidity, particularly of the chest wall
• Convulsions
• Pulmonary oedema
• Toxic leukoencephalopathy (a rare brain condition)

Treatment of overdose involves immediate airway management with assisted ventilation, administration of the opioid antagonist naloxone (which rapidly reverses fentanyl's effects), and cardiovascular support with intravenous fluids and vasopressors as needed. Because fentanyl's duration of action may exceed that of naloxone, repeated doses or a continuous infusion of the antagonist may be necessary, along with prolonged clinical monitoring.

What Are the Side Effects of Fentanyl B. Braun?

Not all patients experience side effects, and most adverse reactions are well-recognised consequences of opioid pharmacology that can be anticipated and managed by the anaesthetic team. However, some side effects are serious and require immediate medical attention. The frequency classifications below follow EMA guidelines.

Additional Side Effects in Children

In paediatric patients, movement disorders, increased pain sensitivity (hyperalgesia), and withdrawal symptoms have been observed following prolonged treatment. Children may be more susceptible to chest wall rigidity than adults, particularly with rapid intravenous injection. Close monitoring of respiratory function is essential in all paediatric patients receiving fentanyl.

Reporting Side Effects

Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national pharmacovigilance authority. Reporting helps to continuously monitor the benefit–risk balance of medicines and contributes to the ongoing safety surveillance of pharmaceutical products.

How Should You Store Fentanyl B. Braun?

As a controlled substance and hospital-only medication, Fentanyl B. Braun is subject to strict storage and handling regulations. In clinical settings, it is stored in locked, controlled-access drug cabinets with auditable dispensing records. The following storage guidance applies to the product itself:

• Keep out of sight and reach of children at all times.
• No special temperature storage requirements. Store at ambient room temperature.
• Keep ampoules in the original outer carton to protect from light. The solution is light-sensitive.
• Do not use after the expiry date printed on the label and carton (marked “EXP”). The expiry date refers to the last day of that month.
• Single-use ampoules only. Discard the ampoule and any unused contents immediately after use. Do not store partially used ampoules.
• Inspect before use: Only use if the solution is clear, colourless, and the ampoule and its seal are undamaged.

Dilution and Preparation

Fentanyl B. Braun may be used undiluted or diluted. Tested dilution proportions include 1:1 and 1:25 with either 0.9% sodium chloride solution or 5% glucose solution. The maximum dilution should not exceed 1 part fentanyl to 25 parts diluent. Do not mix with any other injection or infusion solutions beyond those specified. From a microbiological standpoint, prepared solutions should be used immediately. If not used immediately, storage should not exceed 24 hours at 2–8°C, unless dilution was performed under validated aseptic conditions.

What Does Fentanyl B. Braun Contain?

Understanding the full composition of Fentanyl B. Braun is important for identifying potential allergens and ensuring compatibility with other parenteral products.

Active Substance

The active ingredient is fentanyl, present in the form of fentanyl citrate. Each millilitre of solution contains 50 micrograms of fentanyl. The concentrations per ampoule are:

• 2 ml ampoule: 100 micrograms fentanyl (0.1 mg)
• 10 ml ampoule: 500 micrograms fentanyl (0.5 mg)

Inactive Ingredients (Excipients)

• Sodium chloride: 3.54 mg per ml (tonicity agent to make the solution isotonic with body fluids)
• Water for injections: Highly purified water meeting pharmacopoeial standards for parenteral use

Product Appearance and Packaging

Fentanyl B. Braun injection solution is a clear, colourless aqueous solution supplied in clear, colourless glass ampoules. Each ampoule is for single use only. Available pack sizes are 10 × 2 ml and 10 × 10 ml ampoules.

The product is manufactured by B. Braun Melsungen AG, Carl-Braun Strasse 1, 34212 Melsungen, Germany. It is authorised and marketed in multiple European countries under various trade names, reflecting its established role in European anaesthetic practice.